Cargando…

Immunotherapy for the treatment of Alzheimer’s disease: amyloid-β or tau, which is the right target?

Alzheimer’s disease (AD) is characterized by the presence of amyloid plaques composed mainly of amyloid-β (Aβ) protein. Overproduction or slow clearance of Aβ initiates a cascade of pathologic events that may lead to formation of neurofibrillary tangles, neuronal cell death, and dementia. Although i...

Descripción completa

Detalles Bibliográficos
Autores principales:	Castillo-Carranza, Diana L, Guerrero-Muñoz, Marcos J, Kayed, Rakez
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2013
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4918231/ https://www.ncbi.nlm.nih.gov/pubmed/27471697 http://dx.doi.org/10.2147/ITT.S40131

Ejemplares similares

Alzheimer brain-derived tau oligomers propagate pathology from endogenous tau
por: Lasagna-Reeves, Cristian A., et al.
Publicado: (2012)

α-Synuclein Oligomers Induce a Unique Toxic Tau Strain
por: Castillo-Carranza, Diana L., et al.
Publicado: (2018)

Advances and considerations in AD tau-targeted immunotherapy
por: Bittar, Alice, et al.
Publicado: (2019)

Tau oligomers mediate α-synuclein toxicity and can be targeted by immunotherapy
por: Gerson, Julia E., et al.
Publicado: (2018)

The Role of Amyloid-β Oligomers in Toxicity, Propagation, and Immunotherapy
por: Sengupta, Urmi, et al.
Publicado: (2016)

Tau oligomers in cerebrospinal fluid in Alzheimer's disease
por: Sengupta, Urmi, et al.
Publicado: (2017)

The formation of tau pore-like structures is prevalent and cell specific: possible implications for the disease phenotypes
por: Lasagna-Reeves, Cristian A, et al.
Publicado: (2014)

Tau Oligomers: The Toxic Player at Synapses in Alzheimer’s Disease
por: Guerrero-Muñoz, Marcos J., et al.
Publicado: (2015)

Comparison of Tau and Amyloid-β Targeted Immunotherapy Nanoparticles for Alzheimer’s Disease
por: Mashal, Yara, et al.
Publicado: (2022)

Aβ/tau oligomer interplay at human synapses supports shifting therapeutic targets for Alzheimer’s disease
por: Marcatti, Michela, et al.
Publicado: (2022)

Quantification and targeting of elusive neurotoxic amyloid oligomers
por: Bhatt, Nemil, et al.
Publicado: (2022)

Prospects for strain-specific immunotherapy in Alzheimer’s disease and tauopathies
por: Bittar, Alice, et al.
Publicado: (2018)

Characterization of tau oligomeric seeds in progressive supranuclear palsy
por: Gerson, Julia E, et al.
Publicado: (2014)

Tau oligomers impair memory and induce synaptic and mitochondrial dysfunction in wild-type mice
por: Lasagna-Reeves, Cristian A, et al.
Publicado: (2011)

Differential Activation of the ER Stress Factor XBP1 by Oligomeric Assemblies
por: Castillo-Carranza, Diana L., et al.
Publicado: (2012)

TAU-INDUCED ASTROCYTE SENESCENCE: A NOVEL MECHANISM FOR NEURONAL DYSFUNCTION IN ALZHEIMER’S DISEASE
por: Olson, Angela, et al.
Publicado: (2019)

Cerebral Microvascular Accumulation of Tau Oligomers in Alzheimer’s Disease and Related Tauopathies
por: Castillo-Carranza, Diana L, et al.
Publicado: (2017)

Formation and Propagation of Tau Oligomeric Seeds
por: Gerson, Julia E., et al.
Publicado: (2013)

Tau Oligomers: Cytotoxicity, Propagation, and Mitochondrial Damage
por: Shafiei, Scott S., et al.
Publicado: (2017)

Infectious etiology and amyloidosis in Alzheimer's disease: The puzzle continues
por: Kayed, Rakez
Publicado: (2021)

The prion-like transmission of tau oligomers via exosomes
por: Jackson, Noel A., et al.
Publicado: (2022)

P53 aggregation, interactions with tau, and impaired DNA damage response in Alzheimer’s disease
por: Farmer, Kathleen M., et al.
Publicado: (2020)

Immunotherapy for Alzheimer’s disease: targeting β-amyloid and beyond
por: Song, Chenghuan, et al.
Publicado: (2022)

Pathological tau signatures and nuclear alterations in neurons, astrocytes and microglia in Alzheimer's disease, progressive supranuclear palsy, and dementia with Lewy bodies
por: Montalbano, Mauro, et al.
Publicado: (2022)

Tau Protein: Function and Pathology
por: Rosenmann, Hanna, et al.
Publicado: (2012)

Passive immunotherapies targeting Aβ and tau in Alzheimer's disease
por: Plotkin, Steven S., et al.
Publicado: (2020)

Flanking regions, amyloid cores, and polymorphism: the potential interplay underlying structural diversity
por: Bhopatkar, Anukool A., et al.
Publicado: (2023)

Tau Oligomers Associate with Inflammation in the Brain and Retina of Tauopathy Mice and in Neurodegenerative Diseases
por: Nilson, Ashley N., et al.
Publicado: (2016)

The Dichotomy of Alzheimer’s Disease Pathology: Amyloid-β and Tau
por: Ashford, J. Wesson
Publicado: (2019)

Alzheimer’s Disease: A Brief History of Immunotherapies Targeting Amyloid β
por: Vogt, Anne-Cathrine S., et al.
Publicado: (2023)

Amyloid Beta Annular Protofibrils in Cell Processes and Synapses Accumulate with Aging and Alzheimer-Associated Genetic Modification
por: Kokubo, Hideko, et al.
Publicado: (2009)

Oligomeric tau-targeted immunotherapy in Tg4510 mice
por: Schroeder, Sulana, et al.
Publicado: (2017)

Anti-amyloid-beta to tau-based immunization: developments in immunotherapy for Alzheimer’s disease
por: Lambracht-Washington, Doris, et al.
Publicado: (2013)

Lysine 63-linked ubiquitination of tau oligomers contributes to the pathogenesis of Alzheimer’s disease
por: Puangmalai, Nicha, et al.
Publicado: (2022)

Interacting Models of Amyloid-β and Tau Proteins: An Approach to Identify Drug Targets in Alzheimer’s Disease
por: Priya, Khadgawat, et al.
Publicado: (2021)

Editorial: Targets for Disease-Modifying Therapies in Alzheimer’s Disease, Including Amyloid β and Tau Protein
por: Parums, Dinah V.
Publicado: (2021)

Elevated phospholipase D isoform 1 in Alzheimer's disease patients' hippocampus: Relevance to synaptic dysfunction and memory deficits
por: Krishnan, Balaji, et al.
Publicado: (2018)

Temporal association patterns and dynamics of amyloid-β and tau in Alzheimer’s disease
por: Ower, Alison K., et al.
Publicado: (2017)

Distinct amyloid-β and tau-associated microglia profiles in Alzheimer’s disease
por: Gerrits, Emma, et al.
Publicado: (2021)

Associations of plasma angiostatin and amyloid-β and tau levels in Alzheimer’s disease
por: Cheng, Yuan, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_26hcnromhm5u3o0us1nrgugrgi